Equity Overview
Price & Market Data
Price: $1.05
Daily Change: -$0.02 / 1.90%
Daily Range: $1.05 - $1.05
Market Cap: $60,884,740
Daily Volume: 6,786
Performance Metrics
1 Week: 13.79%
1 Month: -4.46%
3 Months: 2.88%
6 Months: -49.29%
1 Year: -15.08%
YTD: 7.00%
Company Details
Employees: 142
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.